Search online for treatments addressing postpartum vaginal laxity, perimenopausal dryness, or discomfort during intimacy, and you will encounter an aggressive wave of medical spa marketing. Advertisements promote lunch-time "vaginal rejuvenation," laser tightening, and radiofrequency wand treatments promising to restore youthful elasticity, eliminate genitourinary symptoms of menopause, and enhance sexual wellness in three 15-minute sessions.
Frequently, these clinic websites prominently display the badge "FDA-Approved."
However, a direct examination of the U.S. Food and Drug Administration (FDA) regulatory record, published adverse event surveillance, and blinded clinical trials reveals a stark contradiction:
- Zero energy-based devices are FDA-approved or 510(k)-cleared for vaginal rejuvenation, vaginal tightening, or treating symptoms of menopause.
- On July 30, 2018, the FDA issued a formal, nationwide Safety Communication warning that energy devices used for vaginal rejuvenation had resulted in serious patient harm—including vaginal burns, scarring, dyspareunia (painful intercourse), and recurring or chronic pelvic pain—and separately notified seven leading device manufacturers by letter, requesting responses within 30 days.
- The underlying laser and radiofrequency platforms (such as MonaLisa Touch, FemiLift, ThermiVa, and Votiva) hold 510(k) clearances strictly as general surgical cutting and coagulating tools—lasers under product code GEX, RF systems under the electrosurgical code GEI—not as rejuvenation or menopause treatments.
- When researchers finally subjected these devices to rigorous, sham-controlled clinical trials (the landmark 2021 JAMA trial, the 2023 BJOG trial, and a 2025 breast-cancer survivor trial), the laser arms demonstrated no statistically significant advantage over sham placebo wands for the core symptom outcomes.
- Meanwhile, highly effective, FDA-approved medical therapies for genitourinary syndrome of menopause (GSM) already exist—including local low-dose vaginal estrogens, oral ospemifene, and vaginal prasterone/DHEA.
Here is the definitive, evidence-graded guide to energy-based vaginal devices: what the FDA cleared versus what marketing claims assert, the complete data from double-blind sham trials, what federal MAUDE safety databases reveal about injuries, the approved medical alternatives, and the exact questions every patient must ask before consenting to an off-label procedure.
Direct Answer: Is Vaginal Laser or RF Rejuvenation FDA-Approved?
No. No laser, radiofrequency, or ultrasound device has ever received FDA approval or 510(k) clearance for "vaginal rejuvenation," vaginal tightening, or treating menopause-related vaginal atrophy. The FDA explicitly warned against these procedures in July 2018 following reports of severe vaginal burns, scarring, and chronic pain. Furthermore, gold-standard double-blind sham-controlled trials have demonstrated that fractional CO₂ laser treatment is no more effective than a deactivated sham device for the core postmenopausal vaginal symptoms at 12 months.
If you are experiencing vaginal dryness, painful intercourse, or tissue laxity, evidence-backed and FDA-approved medical options exist—starting with local vaginal estrogen therapy, non-hormonal prescription prasterone (Intrarosa), oral ospemifene (Osphena), and targeted pelvic floor physical therapy.
┌────────────────────────────────────────────────────────┐
│ THE VAGINAL SYMPTOM REGULATORY & TREATMENT MATRIX │
└───────────────────────────┬────────────────────────────┘
│
▼
┌────────────────────────┬───────────────┴───────────────┬────────────────────────┐
▼ ▼ ▼ ▼
┌──────────────────┐ ┌──────────────────┐ ┌──────────────────┐ ┌──────────────────┐
│ 1. ENERGY-BASED │ │ 2. FDA-APPROVED │ │ 3. FDA-APPROVED │ │ 4. PELVIC FLOOR │
│ DEVICES │ │ TOPICALS │ │ ORAL MEDS │ │ PHYSICAL THER │
├──────────────────┤ ├──────────────────┤ ├──────────────────┤ ├──────────────────┤
│ • Fractional CO2 │ │ • Low-Dose │ │ • Ospemifene │ │ • Certified │
│ (MonaLisa/Fem) │ │ Vaginal │ │ (Osphena oral │ │ Pelvic Floor │
│ • RF (ThermiVa/ │ │ Estrogen │ │ daily SERM) │ │ Physical │
│ Votiva) │ │ • Prasterone │ │ • Dyspareunia & │ │ Therapy │
│ • Status: │ │ (Intrarosa DHEA│ │ GSM label │ │ • High evidence │
│ NOT APPROVED; │ │ vaginal insert)│ │ • Proven in │ │ for laxity & │
│ FDA Warning │ │ • FDA-Approved │ │ Phase 3 trials │ │ incontinence │
└──────────────────┘ └──────────────────┘ └──────────────────┘ └──────────────────┘
Regulatory Reality: The 510(k) General Surgical Clearance Boundary
A primary source of patient confusion is the widespread claim by med spas that their vaginal laser is "FDA-Cleared." While a medical device may possess a 510(k) clearance document from the FDA, the clearance is strictly limited to the specific indication written on the clearance letter.
The 510(k) Database Audit
A comprehensive audit of the FDA CDRH 510(k) premarket notification database across all major energy platforms marketed for vaginal rejuvenation reveals a uniform regulatory classification:
┌────────────────────────────────────────────────────────────────────────────────────────┐
│ 510(k) CLEARANCE AUDIT: POPULAR ENERGY-BASED VAGINAL PLATFORMS │
├─────────────────────┬───────────────────┬──────────────┬───────────────────────────────┤
│ PLATFORM BRAND │ MANUFACTURER / │ 510(k) │ ACTUAL FDA-CLEARED │
│ │ APPLICANT │ NUMBER & CODE│ INDICATION FOR USE │
├─────────────────────┼───────────────────┼──────────────┼───────────────────────────────┤
│ SmartXide Family │ Cynosure / El.En. │ K031224, │ Code GEX: General surgical │
│ (MonaLisa Touch) │ (DEKA) │ K172362, │ cutting, incision, ablation, │
│ │ │ K240497 │ coagulation, vaporization of │
│ │ │ │ soft tissue (including GYN). │
├─────────────────────┼───────────────────┼──────────────┼───────────────────────────────┤
│ FemiLift │ Alma Lasers │ K103501, │ Code GEX: Surgical cutting, │
│ (Pixel CO2 System) │ │ K250071 │ coagulation, vaporization of │
│ │ │ │ body soft tissues. │
├─────────────────────┼───────────────────┼──────────────┼───────────────────────────────┤
│ FemTouch │ Lumenis │ K100415, │ Code GEX: Soft tissue laser │
│ (AcuPulse platform) │ │ K180597 │ vaporization, incision, and │
│ │ │ │ ablation. │
├─────────────────────┼───────────────────┼──────────────┼───────────────────────────────┤
│ ThermiVa │ ThermiGen │ K130689, │ Code GEI: General electrosur- │
│ (RF System) │ │ K173582 │ gical dermatologic and general│
│ │ │ │ soft-tissue coagulation. │
├─────────────────────┼───────────────────┼──────────────┼───────────────────────────────┤
│ Votiva (FormaV) │ InMode │ K171593, │ Code GEI: General electrosur- │
│ │ │ K182325 │ gical coagulation of tissue. │
├─────────────────────┼───────────────────┼──────────────┼───────────────────────────────┤
│ Viveve System │ Viveve Medical │ K212678 │ Code GEI: Electrocoagulation │
│ (Cryogen-cooled RF) │ │ │ of surgical soft tissue. │
└─────────────────────┴───────────────────┴──────────────┴───────────────────────────────┘
The Difference Between Surgical Clearance and Indication Approval
- What FDA Cleared (Code GEX / GEI): These platforms are cleared as general surgical tools. For example, a gynecologic surgeon is legally permitted to use a CO₂ laser to surgically vaporize an abnormal cervical dysplasia (CIN) lesion, excise a condyloma, or coagulate bleeding vessels during pelvic surgery.
- What FDA Did NOT Clear: The FDA has never granted 510(k) clearance or PMA approval for:
- "Vaginal rejuvenation" or cosmetic tightening
- Treatment of Genitourinary Syndrome of Menopause (GSM)
- Treatment of Vulvovaginal Atrophy (VVA)
- Relief of dyspareunia (painful sex) due to estrogen deficiency
- Stress Urinary Incontinence (SUI)
- Vaginal laxity from childbirth
When a commercial aesthetic clinic advertises a fractional laser to "tighten vaginal walls" or "cure menopausal dryness," they are promoting an unapproved, off-label procedure that lacks FDA evaluation of safety and efficacy.
The July 30, 2018 FDA Public Warning
On July 30, 2018, following a surge in adverse event reports and aggressive direct-to-consumer advertising campaigns, the FDA took the rare step of issuing a public safety alert and sending formal regulatory letters to seven leading device manufacturers.
┌────────────────────────────────────────────────────────────────────────────────────────┐
│ THE 2018 FDA SAFETY COMMUNICATION RECORD │
├────────────────────────────────────────┬───────────────────────────────────────────────┤
│ OFFICIAL REGULATORY ACTION │ DETAILS & ENFORCEMENT SUMMARY │
├────────────────────────────────────────┼───────────────────────────────────────────────┤
│ FDA Safety Alert Title │ "FDA warns against use of energy-based │
│ │ devices to perform vaginal 'rejuvenation' │
│ │ or cosmetic vaginal procedures" │
├────────────────────────────────────────┼───────────────────────────────────────────────┤
│ Action Date │ July 30, 2018 │
├────────────────────────────────────────┼───────────────────────────────────────────────┤
│ Manufacturers Notified by Letter │ • Alma Lasers │
│ (30 Days to Respond; Enforcement │ • BTL Aesthetics │
│ Considered Thereafter) │ • BTL Industries │
│ │ • Cynosure │
│ │ • InMode │
│ │ • Sciton │
│ │ • ThermiGen │
├────────────────────────────────────────┼───────────────────────────────────────────────┤
│ Core Regulatory Statement │ "To date, we have not cleared or approved for │
│ │ marketing any energy-based devices to treat │
│ │ these symptoms or conditions, or any symptoms │
│ │ related to menopause, urinary incontinence, or│
│ │ sexual function." │
├────────────────────────────────────────┼───────────────────────────────────────────────┤
│ Specific Patient Harms Cited │ Vaginal burns, tissue scarring, pain during │
│ │ intercourse (dyspareunia), and recurring or │
│ │ chronic pelvic/vaginal pain. │
└────────────────────────────────────────┴───────────────────────────────────────────────┘
In the accompanying FDA statement, Commissioner Scott Gottlieb, M.D., wrote:
"These products have serious risks and don't have adequate evidence to support their use for these purposes. We are deeply concerned women are being harmed."
Gottlieb added that "the deceptive marketing of a dangerous procedure with no proven benefit, including to women who've been treated for cancer, is egregious." The FDA gave the seven manufacturers 30 days to address its concerns, after which it would consider enforcement action.
The Sham-Controlled Trials: What Happens When Laser Is Tested Against Placebo?
Prior to 2021, the clinical literature supporting vaginal lasers consisted almost exclusively of uncontrolled, open-label, single-arm studies (such as the early Pitsouni 2017 meta-analysis in Maturitas, PMID 28778337). In these studies, women receiving laser treatments reported improved symptom scores.
However, in sexual health and pain research, the placebo and procedural attention effect is large—in every sham trial below, the sham arm itself improved, reflecting frequent provider contact, patient optimism, and natural symptom fluctuation.
The true test of any medical technology requires a double-blind, sham-controlled trial, where neither the patient nor the examining physician knows whether the laser actually fired energy into the tissue or used a deactivated sham handpiece.
┌────────────────────────────────────────────────────────────────────────────────────────┐
│ DOUBLE-BLIND SHAM-CONTROLLED TRIALS: FRACTIONAL CO2 VAGINAL LASER │
├───────────────────────┬────────────┬──────────────┬────────────────────────────────────┤
│ TRIAL / PUBLICATION │ STUDY TYPE │ POPULATION │ PRIMARY CLINICAL FINDINGS │
├───────────────────────┼────────────┼──────────────┼────────────────────────────────────┤
│ Li et al. 2021 │ Double- │ 85 post- │ VAS symptom severity difference │
│ JAMA │ blind │ menopausal │ 9.4 points (95% CI -28.6 to 47.5 — │
│ (PMID 34636862) │ Sham-RCT; │ women │ not significant). No difference in │
│ │ 12-month │ (43 laser, │ VSQ, Vaginal Health Index (VHI), │
│ │ follow-up │ 42 sham) │ QoL, or mucosal histology. │
├───────────────────────┼────────────┼──────────────┼────────────────────────────────────┤
│ Page et al. 2023 │ Double- │ 60 women │ Most-bothersome-symptom severity │
│ BJOG │ blind Sham-│ with GSM │ fell 23.6% with laser vs 13.2% │
│ (PMID 36349391) │ RCT │ │ with sham at 12 weeks — not │
│ │ │ │ statistically significant (p=0.13).│
├───────────────────────┼────────────┼──────────────┼────────────────────────────────────┤
│ Jaber et al. 2025 │ Randomized │ 34 breast │ Dyspareunia and intercourse │
│ Cancers │ Sham-RCT │ cancer │ dryness improved in both arms with │
│ (PMID 40227835) │ │ survivors │ no laser advantage; laser arm did │
│ │ │ with GSM │ improve daily dryness, hydration, │
│ │ │ │ and VHI (judged clinically │
│ │ │ │ insufficient by the authors). │
├───────────────────────┼────────────┼──────────────┼────────────────────────────────────┤
│ Li et al. 2025 │ Open-Label │ Extension │ After unblinding, open-label laser│
│ Climacteric │ Extension │ of 2021 JAMA │ produced no more improvement than │
│ (PMID 40569021) │ Cohort │ cohort (n=25)│ the original trial arms — evidence │
│ │ │ │ that blinding drives reported │
│ │ │ │ benefit. │
└───────────────────────┴────────────┴──────────────┴────────────────────────────────────┘
1. The Landmark 2021 JAMA Sham-Controlled Trial
In October 2021, the Journal of the American Medical Association published the definitive randomized, double-blind, sham-controlled trial conducted by Li and colleagues (PMID 34636862):
- Design: 85 postmenopausal women with severe vaginal symptoms were randomized to receive either 3 active fractional CO₂ laser treatments (n=43) or 3 sham treatments (n=42) using a deactivated probe with identical visual and auditory feedback.
- 12-Month Symptom Results: At the 12-month primary endpoint, the mean difference in Visual Analog Scale (VAS) symptom severity between the laser group and the sham group was 9.4 points (95% CI, -28.6 to 47.5)—a finding that was not statistically significant, with a confidence interval spanning zero.
- Quality of Life & Vaginal Health Index: There were zero statistically significant differences between active laser and sham on the Vaginal Symptom Questionnaire (VSQ difference -1.5; 95% CI -5.9 to 3.0), EuroQoL health scores, or objective Vaginal Health Index (VHI) mucosal hydration scores.
- Histologic Biopsy Analysis: Blinded histological analysis of baseline versus 12-month full-thickness vaginal biopsies revealed no significant differences in epithelial thickness, lamina propria collagen remodeling, or vascularity between the laser and sham groups.
2. The 2025 Breast Cancer Survivor Sham Trial
Because breast cancer survivors taking aromatase inhibitors or tamoxifen often cannot use estrogen-based therapies, energy devices were heavily promoted for this population.
In a 2025 randomized, sham-controlled trial published by Jaber and colleagues (Cancers 2025, PMID 40227835) in 34 breast cancer survivors (19 laser, 15 sham):
- Both the active CO₂ laser group and the sham group improved on dyspareunia and intercourse dryness, without a significant advantage of laser over sham on those core sexual-symptom outcomes.
- The laser arm did show statistically greater improvement in daily dryness, vaginal hydration, and Vaginal Health Index scores—but the authors judged the magnitude "clinically insufficient," and open-label continuation to six sessions did not change that conclusion.
Adverse Events & MAUDE Database Findings: What Injuries Occur?
While commercial marketing portrays vaginal laser and RF wands as painless, zero-downtime procedures, peer-reviewed audits of the FDA Manufacturer and User Facility Device Experience (MAUDE) database document a consistent pattern of physical injuries:
┌────────────────────────────────────────────────────────────────────────────────────────┐
│ MAUDE DATABASE ADVERSE EVENT AUDIT: VAGINAL ENERGY DEVICES │
├─────────────────────────┬───────────────────────────────┬──────────────────────────────┤
│ PUBLICATION / DATASET │ STUDY SCOPE │ REPORTED ADVERSE EVENTS │
├─────────────────────────┼───────────────────────────────┼──────────────────────────────┤
│ Ahluwalia et al. 2019 │ 45 distinct events describing │ • Pain (vulvar, bladder, │
│ Lasers Surg Med │ 46 patients, Oct 2015–Jan 2019│ urethral): 19 reports │
│ (PMID 30924953) │ │ • Numbness / burning: 11 │
│ │ │ • 33 of 46 reported chronic │
│ │ │ injury (pain, scarring, │
│ │ │ dyspareunia, disfigurement)│
├─────────────────────────┼───────────────────────────────┼──────────────────────────────┤
│ Burkett et al. 2022 │ 18 manufacturers, 43 products,│ • 82% categorized as physical│
│ Aesthet Surg J │ 39 genitourinary events │ injury (burns, tears, │
│ (PMID 34309680) │ │ chronic pain); 15% device │
│ │ │ malfunction │
├─────────────────────────┼───────────────────────────────┼──────────────────────────────┤
│ MAUDE full-export │ Brand-name keyword screen │ • SmartXide: 73 reports │
│ keyword screen (2026 │ across the public MAUDE │ • MonaLisa Touch: 37 reports │
│ data extract) │ device-event file │ • CO2RE: 9 reports │
│ │ │ • FemiLift: 8 reports │
│ │ │ • FemTouch: 8 reports │
└─────────────────────────┴───────────────────────────────┴──────────────────────────────┘
Surveillance Methodology Note: MAUDE is a passive reporting system: a report documents a complaint submitted to the FDA, not a confirmed injury rate, and counts carry no denominator of treatments performed. Brand-name keyword screens also miss misspellings and events filed under different product names. Published audits (Ahluwalia, Burkett) applied their own case-definition criteria, which is why their counts are lower than a raw keyword screen.
Common Injury Mechanisms
- Full-Thickness Mucosal Thermal Burns: Overlapping laser pulses or excessive radiofrequency power delivered to thin, postmenopausal vaginal mucosa can produce second- and third-degree thermal burns.
- Vaginal Stenosis & Cicatricial Scarring: As deep thermal burns heal, fibrous scar tissue contracts, narrowing the vaginal canal (stenosis) and making sexual intercourse permanently painful or impossible.
- Pudendal Nerve Irritation & Neuropathic Pain: High thermal energy delivered near the introitus can damage superficial branches of the pudendal nerve, resulting in chronic, intractable vulvodynia and burning pelvic pain.
What IS FDA-Approved for Menopause Vaginal Symptoms Instead?
A common tragedy of energy-device marketing is that patients spend thousands of out-of-pocket dollars on unproven lasers while remaining unaware that safe, low-cost, FDA-approved medical therapies exist for the exact same symptoms.
┌────────────────────────────────────────────────────────────────────────────────────────┐
│ FDA-APPROVED MEDICAL THERAPIES FOR GSM & VULVOVAGINAL ATROPHY │
├──────────────────────┬──────────────────────┬─────────────┬────────────────────────────┤
│ THERAPY CLASS & NAME │ ROUTE & DELIVERY │ FDA-APPROVED│ CLINICAL MECHANISM & │
│ │ │ INDICATION │ TRIAL EVIDENCE │
├──────────────────────┼──────────────────────┼─────────────┼────────────────────────────┤
│ Low-Dose Vaginal │ Vaginal cream, │ Moderate to │ Restores vaginal mucosal │
│ Estrogen │ tablet (Vagifem), │ severe VVA, │ glycogen, lactobacilli, and│
│ (Estradiol / Estriol)│ softgel (Imvexxy), │ dyspareunia,│ acidic pH (3.8–4.5); │
│ │ or ring (Estring) │ dryness │ minimal systemic absorption│
├──────────────────────┼──────────────────────┼─────────────┼────────────────────────────┤
│ Oral Ospemifene │ Oral tablet (60 mg │ Moderate to │ Selective Estrogen Receptor│
│ (Osphena) │ once daily with food)│ severe │ Modulator (SERM); tissue- │
│ │ │ dyspareunia │ specific agonist on vaginal│
│ │ │ from VVA │ epithelium; no breast stim.│
├──────────────────────┼──────────────────────┼─────────────┼────────────────────────────┤
│ Vaginal Prasterone │ Vaginal insert │ Moderate to │ Inactive DHEA precursor │
│ (Intrarosa / DHEA) │ (6.5 mg nightly) │ severe │ converted intracellularly │
│ │ │ dyspareunia │ into estrogen/androgen with│
│ │ │ from GSM │ zero serum estradiol rise. │
├──────────────────────┼──────────────────────┼─────────────┼────────────────────────────┤
│ Hyaluronic Acid & │ Over-the-counter │ Vaginal │ Non-hormonal hydration; │
│ Polycarbophil Creams │ non-hormonal gel │ dryness & │ restores mucosal moisture │
│ (Replens / Hyalo Gyn)│ │ friction │ binding capacity. │
└──────────────────────┴──────────────────────┴─────────────┴────────────────────────────┘
Clinical Guidance Note: For postmenopausal women with intact uteruses, ultra-low-dose local vaginal estrogens and prasterone do not require co-administration of oral progestins because systemic absorption is negligible. Breast cancer survivors should consult their medical oncologist before starting local therapies.
Professional Society Consensus: ACOG and AUGS Positions
The leading medical authorities in obstetrics and gynecology maintain unified positions regarding energy-based vaginal procedures:
American College of Obstetricians and Gynecologists (ACOG Committee Opinion No. 795, January 2020; PMID 31856125):
"Surgery or procedures to alter sexual appearance or function (excluding procedures performed for clinical indications...) are not medically indicated, pose substantial risk, and their safety and effectiveness have not been established."
ACOG further advises that women "should be informed about the lack of high-quality data that support the effectiveness of genital cosmetic surgical procedures and be counseled about their potential complications, including pain, bleeding, infection, scarring, adhesions, altered sensation, dyspareunia, and need for reoperation."
American Urogynecologic Society (AUGS): In its 2019 clinical consensus process on vaginal energy-based devices, AUGS concluded that based on the available literature, vaginal laser is not recommended for routine treatment of vaginal atrophy or urinary incontinence unless part of a well-designed clinical trial or undertaken with special arrangements for clinical governance, consent, and audit.
The Registered Trial Pipeline: What Large Studies Are Actually Underway
The most common industry talking point is that "large registries are coming" that will validate energy-based vaginal treatments. A look at the actual registration record tempers that claim:
- NCT05953090 (The VALOR Study): Vaginal Atrophy & Long-term Observation of Recovery — a prospective, multi-center study of approximately 2,000 participants sponsored by Stratpharma AG with estimated completion in June 2028. Notably, VALOR evaluates a topical gel dressing for vulvovaginal conditions (vaginal atrophy, lichen sclerosus, lichen simplex chronicus, lichen planus) — not a laser or radiofrequency device.
- A number of mid-sized laser trials for GSM are registered and ongoing on ClinicalTrials.gov, but none has yet published large-scale sham-controlled data. Until such controlled evidence exists, the peer-reviewed clinical standard remains anchored by the 2021 JAMA sham-controlled trial and the smaller sham-controlled studies that followed it.
Patient Checklist: What to Ask Before Considering a Vaginal Device
If a medical spa or aesthetic clinic offers you a laser or radiofrequency vaginal treatment, print or save this clinical checklist and ask the provider these mandatory questions:
┌────────────────────────────────────────────────────────────────────────────────────────┐
│ PATIENT INFORMED CONSENT & SAFETY QUESTION CHECKLIST │
├────────────────────────────────────────────────────────────────────────────────────────┤
│ 1. "Are you aware that the FDA issued a Safety Communication in 2018 stating no │
│ energy device is cleared or approved for vaginal rejuvenation or menopause?" │
├────────────────────────────────────────────────────────────────────────────────────────┤
│ 2. "Why are you recommending an unapproved, cash-pay energy procedure ($1,500–$3,500) │
│ before trying FDA-approved medical therapies (vaginal estrogen, prasterone)?" │
├────────────────────────────────────────────────────────────────────────────────────────┤
│ 3. "Are you aware of the 2021 double-blind JAMA sham trial showing laser was no │
│ better than a placebo wand at 12 months?" │
├────────────────────────────────────────────────────────────────────────────────────────┤
│ 4. "What are your exact medical credentials? Are you a board-certified Gynecologist │
│ (OB/GYN) or Urogynecologist, or is this being performed by a non-physician?" │
├────────────────────────────────────────────────────────────────────────────────────────┤
│ 5. "What is your emergency protocol if thermal burn, severe blistering, or chronic │
│ dyspareunia occurs following treatment?" │
└────────────────────────────────────────────────────────────────────────────────────────┘
For broader guidance on regulatory protections, see our guides on informed consent for off-label aesthetic treatments and the FDA warning on RF microneedling.
Frequently Asked Questions
Is MonaLisa Touch FDA-approved?
No. The MonaLisa Touch platform (the DEKA SmartXide laser line from Italy's El.En. group, historically distributed by Cynosure) holds 510(k) clearances (e.g., K031224, K172362) strictly as a general surgical powered laser tool (Code GEX) for cutting, vaporizing, and coagulating soft tissue. It is not FDA-approved or cleared for vaginal rejuvenation, vaginal tightening, or treating menopause symptoms.
Does health insurance cover vaginal laser treatments?
No. Because vaginal energy treatments are not FDA-approved for any medical condition and are considered elective cosmetic or investigational procedures, private health insurance, Medicare, and Medicaid do not cover them. Patients pay 100% out-of-pocket, typically ranging from $1,500 to $3,500 for a three-session series. In contrast, FDA-approved prescription therapies (such as local vaginal estradiol or generic creams) are routinely covered by standard prescription insurance plans.
Are vaginal laser treatments safe?
Not unconditionally. While many women undergo treatment without immediate complications, federal adverse event databases (FDA MAUDE) and medical literature document significant risks of second- and third-degree mucosal thermal burns, vaginal scarring, canal stenosis, and intractable chronic dyspareunia.
What works better than laser for vaginal dryness and painful sex?
Gold-standard clinical trials demonstrate that local low-dose vaginal estrogen (creams, tablets, or rings), vaginal prasterone/DHEA (Intrarosa), and oral ospemifene (Osphena) have superior, proven clinical efficacy for restoring mucosal glycogen, lowering vaginal pH, rebuilding mucosal thickness, and eliminating dyspareunia.
Summary: The Evidence-Based Position
┌────────────────────────────────────────────────────────────────────────────────────────┐
│ THE EVIDENCE-BASED SUMMARY TABLE │
├───────────────────────────────────┬────────────────────────────────────────────────────┤
│ KEY FACTOR │ CLINICAL & REGULATORY STATUS │
├───────────────────────────────────┼────────────────────────────────────────────────────┤
│ FDA Regulatory Approval │ • ZERO devices approved or cleared for vaginal │
│ │ rejuvenation, tightening, or menopause symptoms. │
├───────────────────────────────────┼────────────────────────────────────────────────────┤
│ 2018 FDA Public Safety Warning │ • Active warning issued July 30, 2018 regarding │
│ │ severe burns, scarring, and chronic pain. │
├───────────────────────────────────┼────────────────────────────────────────────────────┤
│ Double-Blind Sham Trial Evidence │ • 2021 JAMA trial (n=85): Laser showed ZERO │
│ │ statistically significant advantage over sham. │
├───────────────────────────────────┼────────────────────────────────────────────────────┤
│ Approved Medical Alternatives │ • Local vaginal estrogens (Estrace/Vagifem) │
│ │ • Vaginal Prasterone / DHEA (Intrarosa) │
│ │ • Oral Ospemifene (Osphena) │
└───────────────────────────────────┴────────────────────────────────────────────────────┘
Sources
- Li FG, Maheux-Lacroix S, Deans R, et al. Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial. JAMA. 2021;326(14):1381-1389. doi:10.1001/jama.2021.14892. PubMed
- Page AS, Verbakel JY, Verhaeghe J, Latul YP, Housmans S, Deprest J. Laser versus sham for genitourinary syndrome of menopause: a randomised controlled trial. BJOG. 2023;130(3):312-319. doi:10.1111/1471-0528.17335. PubMed
- Burkett L, Moalli P, Ackenbom M. What Is Being Reported About Vaginal Lasers? An Examination of Adverse Events Reported to the FDA on Energy-Based Devices. Aesthet Surg J. 2022;42(6):689-694. doi:10.1093/asj/sjab299. PubMed | PMC Full Text
- Ahluwalia J, Avram MM, Ortiz AE. Lasers and energy-based devices marketed for vaginal rejuvenation: a cross-sectional analysis of the MAUDE database. Lasers Surg Med. 2019;51(8):671-677. doi:10.1002/lsm.23084. PubMed
- Jaber S, Levin G, Ram-Weiner M, Lev-Sagie A. CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Women with Breast Cancer: A Randomized, Sham-Controlled Trial. Cancers. 2025;17(7):1241. doi:10.3390/cancers17071241. PubMed
- Li FG, Knapman BL, Nesbitt-Hawes E, Deans R, Abbott J. The effects of repeat fractional CO2 laser for postmenopausal vaginal symptoms following unblinding from a double-blind RCT. Climacteric. 2025;28(6):715-723. doi:10.1080/13697137.2025.2517131. PubMed
- Pitsouni E, Grigoriadis T, Falagas ME, Salvatore S, Athanasiou S. Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas. 2017;103:78-88. doi:10.1016/j.maturitas.2017.06.029. PubMed
- American College of Obstetricians and Gynecologists (ACOG). Committee Opinion No. 795: Elective Female Genital Cosmetic Surgery. Obstet Gynecol. 2020;135(1):e36-e42. doi:10.1097/AOG.0000000000003616. PubMed
- U.S. Food and Drug Administration (FDA). FDA Warns Against Use of Energy-Based Devices to Perform Vaginal "Rejuvenation" or Vaginal Cosmetic Procedures: FDA Safety Communication (July 30, 2018; updated November 20, 2018). Available at: FDA (archived)
- FDA Commissioner Scott Gottlieb, M.D. Statement on efforts to safeguard women's health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for "vaginal rejuvenation" (July 30, 2018). Available at: PRNewswire (FDA release)
- U.S. Food and Drug Administration (FDA). 510(k) Premarket Notification Database: Product Code GEX (Powered Laser Surgical Instrument) and Code GEI (Electrosurgical Coagulation). Available at: FDA.gov
- DailyMed. National Library of Medicine. OSPHENA (ospemifene tablet) Prescribing Information. Available at: DailyMed
- DailyMed. National Library of Medicine. INTRAROSA (prasterone vaginal insert) Prescribing Information. Available at: DailyMed
- ClinicalTrials.gov. NCT05953090: VALOR: Vaginal Atrophy and Long-Term Observation of Recovery Registry Study. Available at: ClinicalTrials.gov
